This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Actos

Takeda Pharmaceutical Company Ltd

Drug Names(s): pioglitazone HCI, Glustin (EU), AD-4833

Description: ACTOS (pioglitazone HCI) is a thiazolidinedione antidiabetic agent that decreases insulin resistance in the periphery and in the liver, resulting in increased insulin-dependent glucosedisposal and decreased hepatic glucose output. Pioglitazone is a potent and highly selectiveagonist for peroxisome proliferator-activated receptor-gamma (PPARg). Activation of PPARg nuclear receptorsmodulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism.

Actos' drug revenues are recorded from Takeda's financial reports and BioMedTracker's listed US Revenue is recorded by Takeda as Americas.

Deal Structure: Revenue splits for this drug are BioMedTracker estimates.

Takeda and Eli Lilly
On May 26, 1998, Eli Lilly and Company and Takeda Chemical Industries entered into a marketing collaboration to copromote Takeda's pioglitazone. Under the collaboration, Takeda will form its own independent affiliate in the U.S. Both Lilly and Takeda will primarily be compensated through a copromotion fee.

In April 2006, Takeda Pharmaceutical Company announced the conclusion of the marketing collaboration in the United States between its wholly owned subsidiary, Takeda Pharmaceuticals North America, and Eli Lilly and Company to promote ACTOS. Takeda will now assume all marketing and sales responsibilities of ACTOS in the U.S. as planned at the outset of the agreement in 1998. Eli Lilly will continue to be a strategic partner of Takeda outside the U.S., by selling ACTOS in Canada, Mexico and parts of Europe and Asia as agreed upon in the original agreement with Takeda.

Pfizer and...See full deal structure in Biomedtracker

Partners: Eli Lilly & Company Pfizer Inc. Zinfandel Pharmaceuticals, Inc.


Actos News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug